The double upgrade from a moderately accurate firm is a bullish catalyst, but insider selling and high short interest create a contrarian tension. Traders should watch for price confirmation above $130.42 before adding long exposure, with a stop below $125.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 12 $132.92entry
- T+1 · 3mo ago +1.98%α +1.28% · $135.55
- T+5 · 3mo ago +14.51%α +14.95% · $152.20
- T+20 · 2mo ago +8.87%α +10.77% · $144.71
- T+60 · 11d ago +10.55%α +15.42% · $146.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Daiwa Capital double-upgraded Merck & Co. (MRK) from Neutral to Outperform on August 12, 2026, raising its price target to $143 from $120, implying 9.6% upside from the current $130.42. The firm has a 52% accuracy rate on 21 calls with a 6.7% average return. Consensus is bullish: 25 of 36 analysts rate MRK Buy or Strong Buy, 11 rate Hold, and none rate Sell. The mean target is $136.85, median $141.50, with a high of $155 and low of $105. Daiwa's $143 target sits above the mean but below the median. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days, though EPS revisions have been mixed with 2 downward revisions in the current quarter. Insider selling occurred on August 5-6, with five transactions totaling ~$3.3 million, including a $1.97 million sale by Guindo Chirfi. Institutional activity is mixed, with one large add and two trims. Short interest is elevated at 56.8% of TRF volume. The double upgrade from a moderately accurate firm is a notable bullish signal, but insider selling and high short interest warrant caution.
Impact Score
Consensus & Targets
Consensus is bullish: 9 Strong Buy, 16 Buy, 11 Hold, 0 Sell, 0 Strong Sell across 36 analysts. The majority (69%) rate MRK a Buy or Strong Buy, with no bearish ratings. Daiwa's Outperform aligns with the bullish consensus direction.
Current price: $130.42. Mean target: $136.85 (4.9% upside). Median: $141.50 (8.5% upside). High: $155 (18.8% upside). Low: $105 (19.5% downside). Daiwa's $143 PT is above the mean and median, implying 9.6% upside, placing it in the upper quartile of targets.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-12 | Daiwa Capital | upgrade | Outperform | $143.00 |
| 2026-08-11 | Argus Research | maintain | Buy | $145.00 |
| 2026-08-05 | Guggenheim | maintain | Buy | $146.00 |
| 2026-07-29 | Barclays | maintain | Overweight | $150.00 |
| 2026-07-13 | JP Morgan | maintain | Overweight | $140.00 |
| 2026-07-13 | BMO Capital | maintain | Outperform | $142.00 |
| 2026-07-13 | Guggenheim | maintain | Buy | $145.00 |
| 2026-07-09 | Morgan Stanley | maintain | Equal-Weight | $113.00 |
| 2026-07-08 | RBC Capital | reiterate | Outperform | $142.00 |
| 2026-07-08 | Wells Fargo | maintain | Overweight | $150.00 |
30-day analyst activity: 1 upgrade (Daiwa), 0 downgrades. EPS revisions show a mixed trend: current quarter (0q) EPS estimates fell from $2.30 to $2.22 over 30 days with 2 downward revisions; next quarter (+1q) estimates are flat; full-year 0y estimates edged down from $2.71 to $2.74 (net 1 up, 2 down). Overall, estimates are being revised slightly lower.
Firm Track Record: Daiwa Capital
Daiwa Capital accuracy: 52% on 21 calls | avg return: 6.7%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 12 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Deutsche Bank | 100% | 2/2 | 9.7% | top tier |
| BMO Capital | 50% | 2/4 | 0.7% | below average |
| Morgan Stanley | 43% | 3/7 | 2.8% | below average |
| Wells Fargo | 40% | 2/5 | 3.8% | below average |
| B of A Securities | 33% | 1/3 | -0.2% | below average |
| Guggenheim | 25% | 1/4 | -7.8% | below average |
| Truist Securities | 20% | 1/5 | -10.3% | below average |
| Cantor Fitzgerald | 9% | 1/11 | -5.5% | below average |
| Barclays | 0% | 0/2 | -7.6% | below average |
| Berenberg | 0% | 0/2 | 11.6% | below average |
Daiwa Capital has a 52% accuracy rate on 21 calls with a 6.7% average return, ranking near the middle of firms covering MRK. The best-performing firm is Deutsche Bank (100% on 2 calls, 9.7% avg return). The worst is Cantor Fitzgerald (9% on 11 calls, -5.5% avg return). Daiwa's accuracy is above the median of the peer set.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $2.22 | $2.01 to $2.41 | $17.3B | ↑0 ↓0 |
| +1q | $1.95 | $1.86 to $2.08 | $16.9B | ↑0 ↓0 |
| 0y | $2.74 | $2.62 to $2.87 | $67.1B | ↑0 ↓0 |
| +1y | $9.55 | $8.33 to $10.36 | $70.3B | ↑0 ↓0 |
Cross-Platform Signals
Insider trades: 5 sales totaling ~$3.3M on Aug 5-6, including a $1.97M sale by Guindo Chirfi and $789K by Richard DeLuca. These sales oppose the bullish upgrade, creating a bearish divergence. Institutional activity is mixed: Zurich Cantonalbank added 44.7% ($190M), while First Trust Advisors trimmed 42% ($333M) and M&G trimmed 29.2% ($27M). Short interest is elevated at 56.8% of TRF volume, indicating significant bearish positioning. No congressional trades reported.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
34 reports on MRK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20263d ago 144 Neutral 2/10 Entry $146.91 Now $144.52 −1.63% settles Feb 11
- Nov 9, 20267d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $144.52 −2.38% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.52 −0.10% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.52 +0.10% settles Feb 1
- Nov 2, 202613d ago 144 Neutral 2/10 Entry $144.67 Now $144.52 −0.10% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.52 −1.24% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.52 −0.52% settles Jan 21
- Oct 21, 202626d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.52 −1.85% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.52 −0.98% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.52 −0.98% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers